Pedro Pablo Martínez-Vega

Pedro Pablo Martínez-Vega

Auto-generated profile, based on publicly available information

Pedro Pablo Martínez-Vega

Affiliation Laboratorio de Parasitología, Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán, Mérida, México

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Vaccine
Verified
Journal Article
Closed access
VMViridiana Martinez-Campos
Viridiana Martinez-Campos
PMPedro Martinez-Vega
Pedro Martinez-Vega
MRMaria Jesus Ramirez-Sierra
Maria Jesus Ramirez-Sierra
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
CSChristopher A. Seid
Christopher A. Seid
Eric DumonteilEric Dumonteil
Eric Dumonteil

21 September 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
Juan José de la Cruz LópezJuan José de la Cruz López
Juan José de la Cruz López
LVLiliana Villanueva-Lizama
Liliana Villanueva-Lizama
VDVictor Dzul-Huchim
Victor Dzul-Huchim
MRMaría-Jesus Ramírez-Sierra
María-Jesus Ramírez-Sierra
PMPedro Martinez-Vega
Pedro Martinez-Vega
Eric DumonteilEric Dumonteil
Eric Dumonteil
A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA and nucleic acid vaccines produce less than optimal responses in humans, our strategy relies on administering a recombinant protein-based vaccine, together with adjuvants that promote Th1-type immunity. Here we describe a process for the purification and refolding of recombinant TSA-1 expressed in Escherichia coli. The overall yield (20–25%) and endotoxin level of the purified recombinant TSA-1 (rTSA-1) is suitable for pilot scale production of the antigen for use in phase 1 clinical trials. Mice infected with T. cruzi were treated with rTSA-1, either alone or with Toll-like receptor 4 (TLR-4) agonist adjuvants including monophosphoryl lipid A (MPLA), glucopyranosyl lipid A (GLA, IDRI), and E6020 (EISEI, Inc). TSA-1 with the TLR-4 agonists was effective at reducing parasitemia relative to rTSA-1 alone, although it was difficult to discern a therapeutic effect compared to treatment with TLR-4 agonists alone. However, rTSA-1 with a 10 ug dose of MPLA optimized reductions in cardiac tissue inflammation, which were significantly reduced compared to MPLA alone. It also elicited the lowest parasite burden and the highest levels of TSA-1-specific IFN-gamma levels and IFN-gamma/IL-4 ratios. These results warrant the further evaluation of rTSA-1 in combination with rTc24 in order to maximize the therapeutic effect of vaccine-linked chemotherapy in both mice and non-human primates before advancing to clinical development.

28 July 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CTChristian Teh-Poot
Christian Teh-Poot
ETEvelyn Tzec-Arjona
Evelyn Tzec-Arjona
PMPedro Martínez-Vega
Pedro Martínez-Vega
MRMaria Jesus Ramirez-Sierra
Maria Jesus Ramirez-Sierra
MRMiguel Rosado-Vallado
Miguel Rosado-Vallado
Eric DumonteilEric Dumonteil
Eric Dumonteil
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, and activation of CD8+ T cells is crucial for a protective immune response. Therefore, the identification of antigens with major histocompatibility complex class I epitopes is a crucial step for vaccine development against T. cruzi. Our aim was to identify novel antigens and epitopes by immunoinformatics analysis of the parasite proteome (12 969 proteins) and to validate their immunotherapeutic potential in infected mice. We identified 172 predicted epitopes, using NetMHC and RANKPEP. The corresponding protein sequences were reanalyzed to generate a consensus prediction, and 26 epitopes were selected for in vivo validation. The interferon γ (IFN-γ) recall response of splenocytes from T. cruzi–infected mice confirmed that 10 of 26 epitopes (38%) induced IFN-γ production. The immunotherapeutic potential of a mixture of all 10 peptides was evaluated in infected mice. The therapeutic vaccine was able to control T. cruzi infection, as evidenced by reduced parasitemia, cardiac tissue inflammation, and parasite burden and increased survival. These findings illustrate the benefits of this approach for the rapid development of a vaccine against pathogens with large genomes. The identified peptides and the proteins from which they are derived are excellent candidates for the development of a vaccine against T. cruzi.

14 October 2023 in Acta Tropica
Verified
Journal Article
Closed access
JMJoel Israel Moo-Millan
Joel Israel Moo-Millan
AHAnette Hernández-Andrade
Anette Hernández-Andrade
IMIrving Jesús May-Concha
Irving Jesús May-Concha
TMTeresa de Jesús Montalvo-Balam
Teresa de Jesús Montalvo-Balam
AAAudrey Arnal
Audrey Arnal
EWEtienne Waleckx
Etienne Waleckx

1 January 2014 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
JCJulio Vladimir Cruz-Chan
Julio Vladimir Cruz-Chan
AAAmarú del Aguilar-Cetina
Amarú del Aguilar-Cetina
LVLiliana Estefanía Villanueva-Lizama
Liliana Estefanía Villanueva-Lizama
PMPedro Pablo Martínez-Vega
Pedro Pablo Martínez-Vega
MRMaria Jesús Ramírez-Sierra
Maria Jesús Ramírez-Sierra
Eric DumonteilEric Dumonteil
Eric Dumonteil
Cutaneous leishmaniasis is a tropical disease affecting over one million patients annually and Leishmania (L.) mexicana is one of the major etiological agents in the Americas. Here we established the first experimental infection of L. (L.) mexicana in canids. Beagle dogs were infected intradermally with culture-derived L. (L.) mexicana. We followed skin ulcer development, histopathological signs, parasite burden and the immune status of the infected dogs. All infected dogs developed uniform oval-craterform ulcers similar to those observed in humans, associated with mixed T helper 1/T helper 2 immune responses. Parasites were detected in the healed lesions 15 weeks post-infection. Higher anti-Leishmania IgG levels correlated with larger lesions and high IgG1/IgG2 ratio was associated with some level of splenomegaly. The canine model described in this work will be of use for further understanding of L. (L.) mexicana immunopathogenensis, and for drug and vaccine development.

1 April 2016 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
NQNir Qvit
Nir Qvit
DSDeborah Schechtman
Deborah Schechtman
DPDarlene Aparecida Pena
Darlene Aparecida Pena
DBDenise Aparecida Berti
Denise Aparecida Berti
CSChrislaine Oliveira Soares
Chrislaine Oliveira Soares
DMDaria Mochly-Rosen
Daria Mochly-Rosen
Parasitic diseases cause ∼ 500,000 deaths annually and remain a major challenge for therapeutic development. Using a rational design based approach, we developed peptide inhibitors with anti-parasitic activity that were derived from the sequences of parasite scaffold proteins LACK (Leishmania's receptor for activated C-kinase) and TRACK (Trypanosoma receptor for activated C-kinase). We hypothesized that sequences in LACK and TRACK that are conserved in the parasites, but not in the mammalian ortholog, RACK (Receptor for activated C-kinase), may be interaction sites for signaling proteins that are critical for the parasites' viability. One of these peptides exhibited leishmanicidal and trypanocidal activity in culture. Moreover, in infected mice, this peptide was also effective in reducing parasitemia and increasing survival without toxic effects. The identified peptide is a promising new anti-parasitic drug lead, as its unique features may limit toxicity and drug-resistance, thus overcoming central limitations of most anti-parasitic drugs.